2.44
+0.03(+1.24%)
Currency In USD
| Previous Close | 2.41 |
| Open | 2.42 |
| Day High | 2.47 |
| Day Low | 2.36 |
| 52-Week High | 25.7 |
| 52-Week Low | 2.2 |
| Volume | 21,534 |
| Average Volume | 198,022 |
| Market Cap | 6.8M |
| PE | -0.22 |
| EPS | -11.3 |
| Moving Average 50 Days | 2.66 |
| Moving Average 200 Days | 6.52 |
| Change | 0.03 |
If you invested $1000 in SeaStar Medical Holding Corporation (ICU) since IPO date, it would be worth $0.95 as of February 21, 2026 at a share price of $2.44. Whereas If you bought $1000 worth of SeaStar Medical Holding Corporation (ICU) shares 3 years ago, it would be worth $3.49 as of February 21, 2026 at a share price of $2.44.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)
GlobeNewswire Inc.
Feb 09, 2026 1:20 PM GMT
Strong survival data extending to 90 days Real-world experience shows results consistent with clinical trial data Favorable safety profile – no device-related adverse events DENVER, Feb. 09, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporat
SeaStar Medical to Present at Upcoming Noble Capital Markets Emerging Growth Virtual Equity Conference
GlobeNewswire Inc.
Jan 29, 2026 1:25 PM GMT
DENVER, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, annou
SeaStar Medical Announces 2026 Milestones
GlobeNewswire Inc.
Jan 07, 2026 1:13 PM GMT
Drive adoption of QUELIMMUNE for ultra-rare pediatric AKI, expanding revenue and doubling the customer base Advance SeaStar Medical’s first-in-class SCD therapy for the adult AKI indication – a potential $4.5 billion market – through completion of en